Hide-and-seek can lead to higher drug prices.

Anne-Lise Berthier

Biotech/Pharma/Bioproduction expert analyst - Member of G&CTI Think Tank and Polepharma

Published Feb 18, 2021

This UZH study shows that rebate systems may hamper patient access to drugs. In the medium term, this practice can even lead to increasing drug prices. #healthcare #drugpricing #policy

To view or add a comment, sign in

More articles by Anne-Lise Berthier

Nanobiotix subsidiary Curadigm secures new collaboration agreement with Sanofi focused on gene therapy pipeline

Jan 25, 2021

Nanobiotix subsidiary Curadigm secures new collaboration agreement with Sanofi focused on gene therapy pipeline

Nanobiotix subsidiary, Curadigm, submitted a research project involving its Nanoprimer technology which was selected…
l’Institut Pasteur arrête le développement d’un de ses candidats vaccins

Jan 25, 2021

l’Institut Pasteur arrête le développement d’un de ses candidats vaccins

La décision de ne pas poursuivre le développement du candidat vaccin basé sur le virus du vaccin contre la rougeole…
Using precision medicine to uncover and treat new skeletal disorders

Dec 23, 2020

Using precision medicine to uncover and treat new skeletal disorders

Researchers of the “Cell Biology and Physiology-LABRET” group of the University of Malaga (UMA), together with the…
Allogene Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Advancement of Allogeneic CAR T Therapy (AlloCAR T™)

Oct 16, 2020

Allogene Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Advancement of Allogeneic CAR T Therapy (AlloCAR T™)
Clean Cells et Xenothera, deux acteurs d’Atlanpole Biothérapies dans la lutte contre le SARS-COV-2

Sep 16, 2020

Clean Cells et Xenothera, deux acteurs d’Atlanpole Biothérapies dans la lutte contre le SARS-COV-2

Test de détection du SARS-COV-2 dans les substances actives et les produits finis destinés aux industries de santé…
Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2

Jul 13, 2020

Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2

Pfizer and BioNTech announced that two of the companies’ four investigational vaccine candidates from their BNT162…
Offre d'achat amicale d'OncoDNA sur Integragen : rapprochement pertinent pour la médecine de précision en oncologie

Jul 9, 2020

Offre d'achat amicale d'OncoDNA sur Integragen : rapprochement pertinent pour la médecine de précision en oncologie

La société belge OncoDNA, spécialiste du théranostic en oncologie, va lancer une offre publique d'achat amicale sur le…
L'AFCROs se dote d'un nouveau site internet

Jul 6, 2020

L'AFCROs se dote d'un nouveau site internet

Au delà d'arborer un design plus moderne, le site offre désormais une meilleure navigation ainsi que des contenus…
Projet de reprise de la société FamarLyon

Jun 28, 2020

Projet de reprise de la société FamarLyon

La société de biotechnologie Neovacs, en partenariat avec la société d'investissement Industry et le family office…
« AAV-Based Gene Therapy Products: Ongoing Clinical Trials »

Jun 15, 2020

« AAV-Based Gene Therapy Products: Ongoing Clinical Trials »

More than 80 AAV-based gene therapy products are at the clinical stage. There are currently more than 110 trials of…

See all articles

Hide-and-seek can lead to higher drug prices.

Anne-Lise Berthier

Biotech/Pharma/Bioproduction expert analyst - Member of G&CTI Think Tank and Polepharma

More articles by Anne-Lise Berthier

Insights from the community

Others also viewed

FDA Resiliency Roadmap for Inspectional Oversight

In the last one decade patient understanding of self-medication develop many fold result in high sales volume of OTC.

Managing Drug Spend

HARM REDUCTION IS LONG-TERM PALLIATIVE CARE FOR DRUG ADDICTS.

Codeine painkillers targeted as GPs & Pharmacists step up turf war!

What happened to drug prices for older Americans?

Pharmaceutical leaders must step up against AMR to save lives across the globe: Courtney Soulsby, Global Director, BSI (British Standards Institution)

340B Dispute Process Proposed by HRSA

Speeding up aseptic processes

Health Policy Weekly - September 23

Explore topics

More articles by Anne-Lise Berthier

Nanobiotix subsidiary Curadigm secures new collaboration agreement with Sanofi focused on gene therapy pipeline

l’Institut Pasteur arrête le développement d’un de ses candidats vaccins

Using precision medicine to uncover and treat new skeletal disorders

Allogene Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Advancement of Allogeneic CAR T Therapy (AlloCAR T™)

Clean Cells et Xenothera, deux acteurs d’Atlanpole Biothérapies dans la lutte contre le SARS-COV-2

Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2

Offre d'achat amicale d'OncoDNA sur Integragen : rapprochement pertinent pour la médecine de précision en oncologie

L'AFCROs se dote d'un nouveau site internet

Projet de reprise de la société FamarLyon

« AAV-Based Gene Therapy Products: Ongoing Clinical Trials »

Insights from the community

Others also viewed

FDA Resiliency Roadmap for Inspectional Oversight

In the last one decade patient understanding of self-medication develop many fold result in high sales volume of OTC.

Managing Drug Spend

HARM REDUCTION IS LONG-TERM PALLIATIVE CARE FOR DRUG ADDICTS.

Codeine painkillers targeted as GPs & Pharmacists step up turf war!

What happened to drug prices for older Americans?

Pharmaceutical leaders must step up against AMR to save lives across the globe: Courtney Soulsby, Global Director, BSI (British Standards Institution)

340B Dispute Process Proposed by HRSA

Speeding up aseptic processes

Health Policy Weekly - September 23

Explore topics